Australia

Fibocom Showcases Smart Connectivity Solutions for AIoT at ElectroneX 2026

SYDNEY, June 3, 2026 /PRNewswire/ -- Fibocom showcased its latest AIoT innovations at ElectroneX 2026 in Australia from June 3–4 at booth D36 under the theme "Intelligent Connectivity for a Smarter World." Targeting the ANZ market, Fibocom presented wireless connectivity solutions for smart payme...

2026-06-03 16:52 2728

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Highlights: * Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements * Increase in sample size driven by enrolment rate exceeding original expectations ...

2026-05-27 22:41 4608

World's smallest deployable operational optical ground station proves capability in successful trials

* Data transferred securely and rapidly between space and ground * Compatible with U.S. Space Development Agency standard * UK Space Minister Liz Lloyd welcomed the news * Units for purchase and service contracts available OXFORD, England, May 27, 2026 /PRNewswire/ -- Archangel Lightworks, ...

2026-05-27 15:00 2974

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncolog...

2026-05-26 19:30 2997

Decision Governance to Enhance Accountability and Transparency of Decisions in Enterprises

The decision governance gap was always there. AI agents just made it impossible to ignore. MELBOURNE, Australia, May 19, 2026 /PRNewswire/ -- FlexRule makes the case that accountability, explainability, and decision quality are not AI problems. They are governance problems that enterprises have ...

2026-05-19 13:52 4011

DAVE & BUSTER'S OPENS IN PERTH AS BRAND CONTINUES GLOBAL EXPANSION

Dave & Buster's makes its Australia debut, expanding its Asia-Pacific footprint Key Highlights * First Dave & Buster's location in Australia opens in Perth. * New venue combines dining, sports viewing and competitive social gaming under one roof. * The opening advances Dave & Buster's conti...

2026-05-19 04:01 3887

Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...

2026-05-15 22:25 8834

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...

2026-05-15 19:06 4519

EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder

* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...

2026-05-14 13:03 2762

Razor Labs Wins Gold Globee® Award for AI Innovation in Mining Fleet Reliability

DataMind AI™ for mobile fleet recognized in the "Anomaly Detection & Pattern Recognition Platform" category SYDNEY, May 12, 2026 /PRNewswire/ -- Razor Labs (TASE: RZR), a global leader in AI-powered predictive maintenance solutions for the mining industry, today announced that it has been named ...

2026-05-12 06:00 2735

(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression

Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity SYDNEY, May 6, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical c...

2026-05-06 19:00 3889

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...

2026-05-06 05:01 3342

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...

2026-04-23 15:00 3492

Proudly Human announces Manager Tools as the world's first officially certified podcast as the world struggles to distinguish between AI-generated and human-created content

SYDNEY, April 22, 2026 /PRNewswire/ -- Proudly Human has announced its certification of all content from global company Manager Tools as human-created, including its three award-winning podcasts, training, and books. This is the first time either a podcast or a p...

2026-04-22 20:32 2839

TeamHive Launches Free Team Effectiveness Indicator, Giving Any Leader or Team Member Instant, Research-Backed Insight Into How Their Team Really Works

HR tech platform, validated by the University of Newcastle, makes its PLUS model diagnostic available at no cost to teams worldwide SYDNEY, April 21, 2026 /PRNewswire/ -- TeamHive (https://team-hive.co/ ), the evidence-based team effectiveness platform, today announced the...

2026-04-22 03:15 2740

Seeing Machines Releases Part 2 of Technical Paper Series on Intoxication

Driver Monitoring System technology enables real-time assessment of a driver's functional state relative to the driving environment CANBERRA, Australia, April 21, 2026 /PRNewswire/ -- Seeing Machines Limited, a global leader in vision-based monitoring technology, has released the second part of ...

2026-04-21 14:00 2725

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originat...

2026-04-15 20:00 5811

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...

2026-04-14 21:02 4445

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative c...

2026-04-02 19:00 5328

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...

2026-03-25 21:01 5807
12345 ... 45